There are currently 441 active clinical trials seeking participants for Breast Cancer research studies. The states with the highest number of trials for Breast Cancer participants are California, Ohio, Illinois and Michigan.
A Study of Breast Cancer Risk Factors and Outcomes of People in Florida
NCT06780176
Recruiting
The purpose of this study is to understand why different people have different risks and outcomes for breast cancer and non-breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2025
Locations: University of California, Los Angeles (Specimen Analysis only), Los Angeles, California +1 locations
Conditions: Breast Cancer, Breast Neoplasms, Breast Diseases
Register for Updates
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
NCT04573231
Recruiting
The purpose of this research is to determine the expression of prostate specific membrane antigen (PSMA) in human epidermal growth factor receptor 2 (HER2)-negative, androgen receptor (AR)-positive metastatic breast cancer, and to determine its role in resistance to the anti-androgen, bicalutamide. The investigators hypothesize that PSMA expression will correlate with resistance to anti-androgen therapies, as has been documented in prostate cancer, and this can be used to select patients most li... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2025
Locations: University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
Conditions: Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
Register for Updates
FHIR-Enhanced RealRisks to Improve Accuracy of Breast Cancer Risk Assessments
NCT05810025
Recruiting
Electronic health records (EHRs) are an increasingly common source for populating risk models, but whether used to populate validated risk assessment models or to de-facto build risk prediction models, EHR data presents several challenges. The purpose of this study is to assess how the integration of patient generated health data (PGHD) and EHR data can generate more accurate risk prediction models, advance personalized cancer prevention, improve digital access to health data in an equitable man... Read More
Gender:
FEMALE
Ages:
Between 35 years and 74 years
Trial Updated:
01/15/2025
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Breast Cancer
Register for Updates
Breast Cancer Pre-habilitation and Prospective Surveillance to Prevent, Detect, and Optimize Physical and Function
NCT06081127
Recruiting
The goal of this research study is to determine the feasibility and potential effects of physical therapy and enhanced patient education delivered before breast cancer treatment. Physical therapy before cancer treatment aims to help with early identification and self-management of physical and functional side effects from cancer treatment. Side effects could be joint pain, muscle weakness, or fatigue that contribute to functional impairment. The main questions this study aims to answer are: 1.... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/14/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Breast Cancer
Register for Updates
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637
Recruiting
The purpose of this study is to determine the safety and efficacy of PF-07220060 with letrozole compared to approved treatments (ie, palbociclib, ribociclib or abemaciclib with letrozole) in people with breast cancer: * HR-positive (breast cancer cells that need estrogen or progesterone to grow) * HER2-negative (cells that have a small amount or none of a protein called HER2 on their surface); * locally advanced (that has spread from where it started to nearby tissue or lymph nodes) or metastat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/14/2025
Locations: Summit Cancer Care, PC, Savannah, Georgia +7 locations
Conditions: Breast Cancer
Register for Updates
Rutgers University Study of the Genetics of Breast Cancer.
NCT06773897
Recruiting
The goal of this observational study is to learn more about how genes impact the risk of breast cancer. Anyone 18 or older living in the US is eligible, and a diagnosis of cancer is NOT required. Study participation is online, and it takes about 20 minutes to complete health surveys and request a saliva collection kit sent through US mail. In return, study participants may opt to receive information about their genetic ancestry at no cost.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/13/2025
Locations: Rutgers University, Piscataway, New Jersey
Conditions: Breast Cancer Risk, Breast Cancer Prevention, Breast Cancer
Register for Updates
A Study of Vericiguat in People With Breast Cancer and Cancer Therapy-Related Cardiac Dysfunction
NCT05806138
Recruiting
The purpose of this study is to find out if adding vericiguat to standard treatment for cancer therapy related cardiac dysfunction (CTRCD) is more effective than standard treatment alone. The addition of vericiguat to the usual treatment could help improve cardiac function, but it could also cause side effects. This study will help researchers find out whether this different treatment is better, the same as, or worse than the usual approach.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/13/2025
Locations: Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York
Conditions: Breast Cancer, Cardiac Dysfunction
Register for Updates
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
NCT05458674
Recruiting
The purpose of this study is to evaluate the safety and efficacy of the three-drug combination of tucatinib, trastuzumab, and eribulin in patients with de novo and recurrent unresectable metastatic HER-2/neu positive breast cancer as assessed by ORR, PFS and OS after prior treatment with a taxane, trastuzumab, and T-DM1.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/10/2025
Locations: University of Colorado, Aurora, Colorado +5 locations
Conditions: Breast Cancer, Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer
Register for Updates
DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
NCT04567420
Recruiting
A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, Estrogen Receptor positive, HER-2 negative breast cancer (DARE)
Gender:
ALL
Ages:
All
Trial Updated:
01/10/2025
Locations: University of Arizona Cancer Center, Tucson, Arizona +14 locations
Conditions: Breast Cancer
Register for Updates
Sexual Health in Breast Cancer Patients
NCT05138510
Recruiting
In the present study, we propose a mixed methods approach to characterize and address the sexual health needs among women with breast cancer at the time of diagnosis and throughout treatment.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: University of Colorado Hospital, Aurora, Colorado
Conditions: Breast Cancer
Register for Updates
A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)
NCT05035836
Recruiting
This is a Phase 2, single-site, single-arm open-label trial of zanidatamab in patients with early stage, low risk HER2+ BC. The primary objective is to determine the efficacy of zanidatamab for patients with early stage HER2/neu positive (HER2+) breast cancer (BC) as determined by pathologic complete response (pCR) .
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/07/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer, HER2-positive
Register for Updates
Empowering Vulnerable and Resilient Latinas to Obtain Breast Cancer Care
NCT05483283
Recruiting
The investigator and study staff will identify, recruit and randomize Latina participants with elevated genetic and Social Determinants of Heath (SDH) risks. Within 1 week of enrollment, all Latina Aim 1 participants in both study arms will engage in three 30-minute, individual, phone-based sessions with the study team across 3 consecutive weeks
Gender:
FEMALE
Ages:
30 years and above
Trial Updated:
01/07/2025
Locations: University of Illinois, Chicago, Illinois
Conditions: Breast Cancer
Register for Updates